These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

707 related items for PubMed ID: 3490435

  • 1. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
    Hinuma S, Naruo K, Shiho O, Tsukamoto K.
    Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
    [Abstract] [Full Text] [Related]

  • 2. Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.
    Hinuma S, Naruo K, Ootsu K, Houkan T, Shiho O, Tsukamoto K.
    Immunology; 1987 Feb; 60(2):173-9. PubMed ID: 3493209
    [Abstract] [Full Text] [Related]

  • 3. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T.
    Cancer Res; 1988 Mar 01; 48(5):1173-9. PubMed ID: 3257715
    [Abstract] [Full Text] [Related]

  • 4. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL, Herberman RB, Olszowy MW, Cramer DV, Salup RR, Reynolds CW, Hiserodt JC.
    Cancer Res; 1988 Feb 15; 48(4):884-90. PubMed ID: 3257412
    [Abstract] [Full Text] [Related]

  • 5. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E, Eisenthal A, Sachs D, Rosenberg SA.
    J Immunol; 1987 Mar 15; 138(6):1992-8. PubMed ID: 3493293
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ, Krosnick JA, Rosenberg SA.
    J Immunol; 1989 Jan 15; 142(2):726-33. PubMed ID: 2783444
    [Abstract] [Full Text] [Related]

  • 9. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
    Butler LD, Browne CP, Layman NK, Riedl P, Tang J, Marder P, DeLong D, Manetta J, Bobbitt L, Strnad J.
    Cancer Res; 1988 Nov 01; 48(21):6081-9. PubMed ID: 3048654
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Generation and characterization of purified adherent lymphokine-activated killer cells in mice.
    Gunji Y, Vujanovic NL, Hiserodt JC, Herberman RB, Gorelik E.
    J Immunol; 1989 Mar 01; 142(5):1748-54. PubMed ID: 2783950
    [Abstract] [Full Text] [Related]

  • 12. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
    Maekawa R, Kitagawa T, Koizumi K, Sato K, Homma M.
    J Biol Response Mod; 1989 Dec 01; 8(6):676-90. PubMed ID: 2600605
    [Abstract] [Full Text] [Related]

  • 13. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T, Belfrage H, Bhiladvala P, Hedlund G.
    J Immunol; 1987 Jun 01; 138(11):3640-5. PubMed ID: 3495566
    [Abstract] [Full Text] [Related]

  • 14. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S, Yamamoto H, Fujii Y, Arai S.
    Cancer Res; 1986 Nov 01; 46(11):5548-52. PubMed ID: 2428480
    [Abstract] [Full Text] [Related]

  • 15. Purification and target cell range of in vivo elicited blast natural killer cells.
    Biron CA, Pedersen KF, Welsh RM.
    J Immunol; 1986 Jul 15; 137(2):463-71. PubMed ID: 3722814
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo.
    Yoshioka T, Sato S, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1986 Aug 15; 77(8):825-32. PubMed ID: 3093429
    [Abstract] [Full Text] [Related]

  • 18. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
    Peace DJ, Kern DE, Schultz KR, Greenberg PD, Cheever MA.
    J Immunol; 1988 May 15; 140(10):3679-85. PubMed ID: 2896213
    [Abstract] [Full Text] [Related]

  • 19. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE, Denis-Mize K, Tang Y, Ye H, Kunich JC, Garrett EN, Peng J, Cousens LS, Gelb AB, Heise C, Wilson SE, Jallal B, Aukerman SL.
    J Immunother; 2007 Jan 15; 30(1):64-74. PubMed ID: 17198084
    [Abstract] [Full Text] [Related]

  • 20. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.
    Yang JC, Mulé JJ, Rosenberg SA.
    J Immunol; 1986 Jul 15; 137(2):715-22. PubMed ID: 2873187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.